Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-Current Assets (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Non-Current Assets for 5 consecutive years, with -$125.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non-Current Assets fell 318.3% year-over-year to -$125.7 million, compared with a TTM value of $43.1 million through Dec 2024, down 81.98%, and an annual FY2024 reading of -$125.7 million, down 318.3% over the prior year.
  • Non-Current Assets was -$125.7 million for Q4 2024 at Barinthus Biotherapeutics, down from $54.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $61.4 million in Q2 2023 and bottomed at -$125.7 million in Q4 2024.
  • Average Non-Current Assets over 5 years is $32.9 million, with a median of $55.8 million recorded in 2022.
  • The sharpest move saw Non-Current Assets skyrocketed 1851.18% in 2021, then tumbled 318.3% in 2024.
  • Year by year, Non-Current Assets stood at $2.8 million in 2020, then surged by 1851.18% to $54.0 million in 2021, then increased by 5.96% to $57.2 million in 2022, then grew by 0.76% to $57.6 million in 2023, then tumbled by 318.3% to -$125.7 million in 2024.
  • Business Quant data shows Non-Current Assets for BRNS at -$125.7 million in Q4 2024, $54.9 million in Q2 2024, and $56.4 million in Q1 2024.